Real-World Insights on Managing Immune-Mediated Thrombotic Thrombocytopenic Purpura with Caplacizumab
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare and life-threatening blood disorder characterized by severe deficiency of the enzyme ADAMTS13, leading to the formation of microthrombi in small blood vessels. This condition requires prompt and effective treatment to prevent serious complications.
Caplacizumab is an innovative nanobody® and cornerstone in the treatment of iTTP.1 This article delves into real-world data from Belgian hospitals on the use of caplacizumab, highlighting its efficacy, safety, and impact on patient outcomes.2
Watch the interview with Prof. Daan Dierickx
Professor Daan Dierickx, a key investigator involved in the study, provides a brief video explanation outlining the research conducted in Belgium and summarizing the primary findings. To learn more about the outcomes of this investigation, click the play button to view the video.
Explore key findings from a comprehensive analysis of hospital data on the management of immune Thrombotic Thrombocytopenic Purpura (iTTP) with caplacizumab.
This retrospective study includes data from adult patients treated in 13 Belgian hospitals between September 2019 and January 2022. The results align with previous clinical trials, confirming the effectiveness and safety of caplacizumab, especially when started early in combination with therapeutic plasma exchange (TPE) and immunosuppressive therapy.2,3 These findings offer valuable insights into optimizing patient care for iTTP.2
For a detailed look at the study and its implications, click below to download the full article.1
Referenties
-
CABLIVI® (caplacizumab) SmPC (accessed on 24/04/2024).
-
Dierickx D, et al. BVTH. 2024;1(2). https://doi.org/10.1016/j.bvth.2024.100008.
-
Scully M, et al. N Engl J Med. 2019;380(4):335-346. https://doi.org/10.1056/NEJMoa1806311.
